Member Info for cj62

@YerDaSellsAvon2 . My assumption is that wyndrone has piped up so in answer to your question and as per usual he has plucked it from his very own A-hole . Best to ignore the sanctimonious twat !!

Is there a video of the q&a ?

If 6013 replicates the mice data in humans I don't think avacta will get to 27. That's what I now think but hopefully p1b data release year end will give us much needed relief from the pains we presently suffer

Aldebaran. What would happen if heights had been forward selling the shares due later this month, someone has been selling sizeable chunks daily ?

Hopefully the avacta landscape will look much improved following all your optimistic assumptions. GLA

Let's just wait for the RNS if that's the case. RAH is quite excitable !!!

BV lets just make sure the horse is attached

Touk so there isn't any chance of a TO when data is revealed end Q2 for Ava 6k or in fact ava 6013 data being released mid 26. Still nothing , just your stake money back ?

Until finance is sorted the CLN MUST be paid in shares

Lets hope so Aldebaran Lets hope so , a change in fortune would be welcome relief for all and I wont ask where said optimism comes from but lets hope its true.

I see the SP is reacting normally to the AGM.

Ice Avacta are a year away from that initial data from AVA 6103 minimum, there isn't enough cash left to get there. Presently no one cares about 12 months time, its the present and the need to clarify the financials going forward as I have said earlier get the financials sorted ie raise immediately (Even at 20p) giving enough cash for the year. As you state This drug uses Exatecan, the same warhead used in Enhertu (the $20bn ADC blockbuster). even with 1 billion shares in issue the pie is enormous and no one will worry about dilution.

Be it a raise, specialist placing or selling a bit of future profits it needs to be sorted and until that point the sp will do what it does.

I am happy if the do a placing at 20p and raise £40 m. If we are right the pie is very big so who cares.

I didn't expect much but that is utterly pointless

And for Yulii Bogatyrenko

Yes. Within biotech business development and strategic commercial roles, Yulii Bogatyrenko is regarded as a seasoned, high-caliber executive. His consistent senior leadership across firms, breadth of therapeutic areas, global market penetration, and public recognition all underline a strong professional reputation.

ChatGPT Says

Dr. Liebowitz is very well-respected — both for his scientific expertise and his ability to advance clinical-stage programs at leading biotech firms. His academic pedigree, industry leadership across multiple companies, and endorsement by a top recruiter all highlight his strong reputation in the field.

Dr. Liebowitz is highly respected by insiders—not only entrusted with key leadership roles but also recognized as a scientific thought leader. His contributions span strategic leadership, clinical program execution, and cutting-edge science. If you're interested, I can explore details like trial outcomes, peer-reviewed publications, or conference feedback—just say the word!

Another 2 expurts joining a sinking ship. Me thinks there's a plan on the horizon and that plan needs funding so I will go as far and me thinks finance is well and truly sorted.

Cant

Roughly 3 months of data, imo they need at least another 3 months and that's data across the 3 indications. End of year is 9 months and that is where we want to be

A partnership for SGC with a lumpy upfront payment, the SP would react very favourably i imagine. See where the SP got too and if high enough.(£1) pay the CLN in shares.